ClinicalTrials.gg
CompletedNCT01518062Updated Jan 18, 2017

Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome

A Phase 4 interventional study of somatropin and somatropin in Genetic Disorder and Turner Syndrome, sponsored by Novo Nordisk A/S. Completed at 1 site in Netherlands. Open to female participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-01-18.

Primary conditionTurner SyndromeRegistry: Genetic Diseases, InbornReclassifiedWhy we changed it
Registry
Genetic Diseases, Inborn — the first condition term the registry derived for this study.
ClinicalTrials.gg
Turner Syndrome
Why
  1. The study's listed conditions name Turner Syndrome, a narrower term within Genetic Diseases, Inborn.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
2 Years to 11 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing Human Growth Hormone in Turner Syndrome — none open to participants now, none under way, none of them phase 3. Human Growth Hormone · Turner Syndrome.

Enrollment
10th of 14
65 · median 108
Started
1989
with 1 other
Phase 4
6 of 14
none open now
Registered
10th of 14
by date
Lead sponsor
4 of 14
Novo Nordisk A/S

Among the 14 studies testing Human Growth Hormone in Turner Syndrome, this one is the 10th largest by enrollment, is one of 2 that started in 1989, is one of 6 in phase 4, and was the 10th registered.

Turner Syndrome

125 studies on the registry are indexed under Turner Syndrome; 33 are open to participants now.

Browse Turner Syndrome studies →

Open to participants now

None of the 14 studies testing Human Growth Hormone in Turner Syndrome is open now. The open studies under Turner Syndrome, anywhere →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Turner Syndrome studies recruiting now, 8 (32%) set no upper age limit and 14 (56%) stop at 75 or younger; 15 take children under 18; 5 take healthy volunteers.

This study: 2 Years to 11 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing Human Growth Hormone in Turner Syndrome as a file.
02

Study summary

This trial is conducted in Europe. The aim of this trial is to assess whether increasing doses of somatropin (Norditropin®) can maintain the initial increase in height velocity and improve final height. This trial has two trial periods, a main period of 4 years and an extension period until final height is reached.

03

Conditions studied

  • Genetic Disorder
  • Turner Syndrome

Browse trials for

04

In context

Turner Syndrome Reclassified

125 studies on the registry are indexed under Turner Syndrome; 33 are open to participants now.

This study's enrollment of 65 is close to the median of 67 across 52 interventional studies indexed under Turner Syndrome.

Browse Turner Syndrome studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Turner Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Genetic Diseases, Inborn. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Turner Syndrome
  • Well documented growth rate during the previous year
  • Height below the 50th percentile for the age in Dutch children
  • Normal thyroid function

Exclusion criteria

Exclusion Criteria:

  • Any endocrine or metabolic disorder
  • Growth failure due to disorders of genitourinary, cardio-pulmonary, gastro-intestinal and nervous systems, nutritional/vitamins deficiencies and chondrodysplasias
  • Patients with hydrocephalus
06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Low dose

    Drug: somatropin · Drug: oestrogen

  • Experimental
    Medium dose

    Drug: somatropin · Drug: oestrogen

  • Experimental
    High dose

    Drug: somatropin · Drug: oestrogen

Interventions

  • 4 IU/m\^2 body surface for 4 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection

  • Initial dose 4 IU/m\^2 body surface the first year, then 6 IU/m\^2 body surface for 3 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection

  • Initial dose 4 IU/m\^2 body surface the first year, then 6 IU/m\^2 body surface, the second year and finally 8 IU/m\^2 body surface for 2 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection

  • Treatment with oestrogen was administered if spontaneous puberty had not occurred by age 12 years and was initiated in the extension period after at least four years of somatropin treatment

07

What researchers measure

Primary outcomes

  1. Final height

Secondary outcomes

  1. Height velocity (cm/year)

  2. Ratio between change in bone age and change in chronological age

  3. Age at onset of puberty

  4. Adverse events

08

Study locations

1 site
  • Novo Nordisk Investigational Site
    Alphen a/d Rijn, Netherlands
09

References and documents

Publications

  • van Teunenbroek A, de Muinck Keizer-Schrama SM, Stijnen T, Jansen M, Otten BJ, Delemarre-van de Waal HA, Vulsma T, Wit JM, Rouwe CW, Reeser HM, Gosen JJ, Rongen-Westerlaken C, Drop SL. Yearly stepwise increments of the growth hormone dose results in a better growth response after four years in girls with Turner syndrome. Dutch Working Group on Growth Hormone. J Clin Endocrinol Metab. 1996 Nov;81(11):4013-21. doi: 10.1210/jcem.81.11.8923853. PubMed 8923853 ↗
  • Sas TC, Gerver WJ, de Bruin R, Stijnen T, de Muinck Keizer-Schrama SM, Cole TJ, van Teunenbroek A, Drop SL. Body proportions during long-term growth hormone treatment in girls with Turner syndrome participating in a randomized dose-response trial. J Clin Endocrinol Metab. 1999 Dec;84(12):4622-8. doi: 10.1210/jcem.84.12.6225. PubMed 10599729 ↗
  • Sas TC, Cromme-Dijkhuis AH, de Muinck Keizer-Schrama SM, Stijnen T, van Teunenbroek A, Drop SL. The effects of long-term growth hormone treatment on cardiac left ventricular dimensions and blood pressure in girls with Turner's syndrome. Dutch Working Group on Growth Hormone. J Pediatr. 1999 Oct;135(4):470-6. doi: 10.1016/s0022-3476(99)70170-8. PubMed 10518081 ↗
  • Van Pareren YK, De Muinck Keizer-Schrama SM, Stijnen T, Sas TC, Drop SL. Effect of discontinuation of long-term growth hormone treatment on carbohydrate metabolism and risk factors for cardiovascular disease in girls with Turner syndrome. J Clin Endocrinol Metab. 2002 Dec;87(12):5442-8. doi: 10.1210/jc.2002-020789. PubMed 12466334 ↗
  • van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, Sas TC, Jansen M, Otten BJ, Hoorweg-Nijman JJ, Vulsma T, Stokvis-Brantsma WH, Rouwe CW, Reeser HM, Gerver WJ, Gosen JJ, Rongen-Westerlaken C, Drop SL. Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab. 2003 Mar;88(3):1119-25. doi: 10.1210/jc.2002-021171. PubMed 12629094 ↗
  • van Pareren YK, Duivenvoorden HJ, Slijper FM, Koot HM, Drop SL, de Muinck Keizer-Schrama SM. Psychosocial functioning after discontinuation of long-term growth hormone treatment in girls with Turner syndrome. Horm Res. 2005;63(5):238-44. doi: 10.1159/000085841. Epub 2005 May 17. PubMed 15900109 ↗
  • Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, Jansen M, Otten BJ, Hoorweg-Nijman JJ, Vulsma T, Massa GG, Rouwe CW, Reeser HM, Gerver WJ, Gosen JJ, Rongen-Westerlaken C, Drop SL. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. J Clin Endocrinol Metab. 1999 Dec;84(12):4607-12. doi: 10.1210/jcem.84.12.6241. PubMed 10599727 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 1989, a primary completion of Sep 2003 and a completion of Sep 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2012
First posted
Jan 25, 2012
Start
Nov 1989
Primary completionActual
Sep 2003
CompletionActual
Sep 2003
Last update
Jan 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01518062
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 25, 2012
Start date
Nov 1989
Primary completion
Sep 2003
Completion
Sep 2003
Last update
Jan 18, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion